Astellas aspires to strike CLDN18.2 gold again with ADC licensing deal worth up to $1.34B
Less than a year after garnering the first anti-CLDN18.2 approval in the U.S., Astellas Pharma is not resting on its laurels. The Japanese pharma giant is doubling down on the star solid tumor target with a new licensing deal for a phase 2 antibody drug conjugate worth up to $1.34 billion.
Less than a year after garnering the first anti-CLDN18.2 approval in the U.S., Astellas Pharma is not resting on its laurels. The Japanese pharma giant is doubling down on the star solid tumor target with a new licensing deal for a phase 2 antibody drug conjugate worth up to $1.34 billion.
